TRANSPEKCommodity Chemicals
Transpek Inds — Cash Flow Statement
₹1392.00
+0.00%
Transpek Inds Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 114.22 Cr | 58.16 Cr | 61.52 Cr | -0.59 Cr | — |
| Repayment Of Debt | -8.16 Cr | -15.69 Cr | -50.73 Cr | -9.50 Cr | — |
| Issuance Of Debt | 0.87 Cr | — | — | 0.00 | 9.60 Cr |
| Capital Expenditure | -20.84 Cr | -39.64 Cr | -49.31 Cr | -47.69 Cr | — |
| End Cash Position | 56.52 Cr | 8.08 Cr | 5.50 Cr | 1.60 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 1000.00 | -1000.00 | -21000.00 | 53000.00 | — |
| Beginning Cash Position | 8.08 Cr | 5.50 Cr | 1.60 Cr | 15.39 Cr | — |
| Changes In Cash | 48.44 Cr | 2.59 Cr | 3.90 Cr | -13.79 Cr | — |
| Financing Cash Flow | -56.17 Cr | -63.69 Cr | -93.91 Cr | 9.21 Cr | — |
| Net Other Financing Charges | 1000.00 | — | — | 3000.00 | -3000.00 |
| Interest Paid Cff | -12.33 Cr | -14.48 Cr | -17.20 Cr | -10.22 Cr | — |
| Cash Dividends Paid | -7.82 Cr | -15.36 Cr | -12.57 Cr | -4.19 Cr | — |
| Net Issuance Payments Of Debt | -7.29 Cr | -15.69 Cr | -50.73 Cr | 34.49 Cr | — |
| Net Short Term Debt Issuance | -8.16 Cr | -7.80 Cr | -43.54 Cr | 43.99 Cr | — |
| Short Term Debt Payments | -8.16 Cr | -7.80 Cr | -43.54 Cr | — | -5.24 Cr |
| Net Long Term Debt Issuance | 0.87 Cr | -7.88 Cr | -7.19 Cr | -9.50 Cr | — |
| Long Term Debt Issuance | 0.87 Cr | — | — | 0.00 | 9.60 Cr |
| Investing Cash Flow | -30.46 Cr | -31.52 Cr | -13.02 Cr | -70.11 Cr | — |
| Net Other Investing Changes | 0.23 Cr | -0.22 Cr | -0.11 Cr | 0.06 Cr | — |
| Interest Received Cfi | 4.62 Cr | 3.33 Cr | 1.71 Cr | 1.49 Cr | — |
| Dividends Received Cfi | 6.31 Cr | 5.73 Cr | 0.40 Cr | 9.00 Cr | — |
| Net Investment Purchase And Sale | -22.68 Cr | -2.31 Cr | 29.53 Cr | -42.74 Cr | — |
| Net Business Purchase And Sale | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Purchase Of Business | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net PPE Purchase And Sale | -18.94 Cr | -38.04 Cr | -44.55 Cr | -37.91 Cr | — |
| Sale Of PPE | 1.90 Cr | 1.60 Cr | 4.76 Cr | 9.78 Cr | — |
| Purchase Of PPE | -20.84 Cr | -39.64 Cr | -49.31 Cr | -47.69 Cr | — |
| Operating Cash Flow | 135.06 Cr | 97.80 Cr | 110.83 Cr | 47.10 Cr | — |
| Taxes Refund Paid | -9.04 Cr | -11.90 Cr | -35.73 Cr | -22.74 Cr | — |
| Change In Working Capital | 25.60 Cr | 12.87 Cr | -22.10 Cr | -49.62 Cr | — |
| Change In Other Current Liabilities | 0.20 Cr | -1.64 Cr | 4.06 Cr | 2.38 Cr | — |
| Change In Other Current Assets | 19.38 Cr | -4.07 Cr | -9.84 Cr | -20.08 Cr | — |
| Change In Payable | 17.89 Cr | -8.52 Cr | 2.10 Cr | 20.55 Cr | — |
| Change In Inventory | -2.78 Cr | 0.87 Cr | 0.92 Cr | -29.42 Cr | — |
| Change In Receivables | -10.10 Cr | 26.09 Cr | -19.45 Cr | -23.06 Cr | — |
| Other Non Cash Items | 6.39 Cr | 10.69 Cr | 17.62 Cr | 8.96 Cr | — |
| Provisionand Write Offof Assets | -0.83 Cr | -16000.00 | -0.06 Cr | -0.24 Cr | — |
| Depreciation And Amortization | 49.99 Cr | 37.60 Cr | 33.02 Cr | 29.73 Cr | — |
| Depreciation | 49.99 Cr | 37.60 Cr | 33.02 Cr | 29.73 Cr | — |
| Gain Loss On Investment Securities | -6.31 Cr | -5.73 Cr | -0.40 Cr | -9.00 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -0.30 Cr | -0.89 Cr | 2.98 Cr | 1.43 Cr | — |
| Gain Loss On Sale Of PPE | 7.91 Cr | -0.35 Cr | 2.70 Cr | 4.35 Cr | — |
| Net Income From Continuing Operations | 61.66 Cr | 55.51 Cr | 112.80 Cr | 84.24 Cr | — |
| Long Term Debt Payments | — | -7.88 Cr | -7.19 Cr | -9.50 Cr | -9.93 Cr |
| Short Term Debt Issuance | — | — | — | 43.99 Cr | 18.04 Cr |
| Purchase Of Investment | — | — | — | -42.74 Cr | -6.07 Cr |
| Amortization Cash Flow | — | — | — | 9000.00 | — |
| Issuance Of Capital Stock | — | — | — | — | 0.01 Cr |
| Net Common Stock Issuance | — | — | — | — | 0.01 Cr |
| Common Stock Issuance | — | — | — | — | 0.01 Cr |
| Capital Expenditure Reported | — | — | — | — | -17.54 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Transpek Inds
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.